K-ras and p16INK4Aalterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers

Lung Cancer

Volumn 44, Issue 1, 2004, Pages 23-32

  Destro, A ^a   Bianchi, P ^a   Alloisio, M ^a   Laghi, L ^a   Di Gioia, S ^a   Malesci, A ^a,b   Cariboni, U ^a   Gribaudi, G ^a   Bulfamante, G ^b   Marchetti, A ^c   Bosari, S ^b   Infante, M ^a   Ravasi, G ^a   Roncalli, M ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

H E; Hematoxylin eosin; Hypermethylation; K ras; Methylation specific PCR; MSP; Non small cell lung carcinoma; NSCLC; p6 INK4A; PCR; PCR RFLP; Polymerase chain reaction; Polymerase chain reaction restriction fragment length polymorphism

Indexed keywords

K RAS PROTEIN; PROTEIN P16; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DIAGNOSTIC TEST; EPIGENETICS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SMOKING; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; TOBACCO DEPENDENCE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SMOKING; SPUTUM;

EID: 12144291697     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.10.002     Document Type: Article

References (42)

1. Minna JD. Harrison's. Principles of internal medicine. McGraw-Hill; 1991.
2. LJ MD. Lung cancer: principles and practice. Lippincott-Raven Publishers; 1996.
3. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S.et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48:1988;5738-5741.
4. Mitsudomi T., Steinberg S.M., Oie H.K., Mulshine J.L., Phelps R., Viallet J.et al. K-ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51:1991;4999-5002.
5. Rodenhuis S. K-ras and human tumors. Semin. Cancer Biol. 3:1992;241-247.
6. Husgafvel-Pursiainen K., Hackman P., Ridanpaa M., Anttila S., Karjalainen A., Partanen T.et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int. J. Cancer. 53:1993;250-256.
7. Li S., Rosell R., Urban A., Font A., Ariza A., Armengol P.et al. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer. 11:1994;19-27.
8. Rodenhuis S., Slebos R.J. The ras oncogenes in human lung cancer. Am. Rev. Respir. Dis. 142:1990;S27-S30.
9. Rosell R., Li S., Skacel Z., Mate J.L., Maestre J., Canela M.et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 8:1993;2407-2412.
10. Mao L., Hruban R.H., Boyle J.O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54:1994;1634-1637.
11. Mills N.E., Fishman C.L., Rom W.N., Dubin N., Jacobson D.R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55:1995;1444-1447.
12. Somers V.A., Pietersen A.M., Theunissen P.H., Thunnissen F.B. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J. Clin. Oncol. 16:1998;3061-3068.
13. Steven F.S., Katsumi T., Payne P.W., Denton J. Evidence for the induction of a tumour associated cell surface protease on cytologically normal epithelial cells present in the sputum of patients possessing lung tumours. Anticancer Res. 19:1999;3491-3493.
14. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
15. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A.et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:1996;3415-3420.
16. Sanchez-Cespedes M., Reed A., Buta M., Wu L., Westra W., Herman J.et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene. 18:1999;5843-5849.
17. Vonlanthen S., Heighway J., Tschan M., Borner M., Altermatt H., Kappeler A.et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 17:1998;2779-2785.
18. de Vos S., Miller C.W., Takeuchi S., Gombart A.F., Cho S.K., Koeffler H.P. Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes Cancer. 14:1995;164-170.
19. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
20. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T.et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 55:1995;514-517.
21. Rusin M.R., Okamoto A., Chorazy M., Czyzewski K., Harasim J., Spillare E.A.et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer. 65:1996;734-739.
22. Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., Demetrick D.J.et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55:1995;1448-1451.
23. Marchetti A., Buttitta F., Pellegrini S., Bertacca G., Chella A., Carnicelli V.et al. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J. Pathol. 181:1997;178-182.
24. Betticher D.C., White G.R., Vonlanthen S., Liu X., Kappeler A., Altermatt H.J.et al. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int. J. Cancer. 74:1997;556-562.
25. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C.et al. 5′-CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
26. Kashiwabara K., Oyama T., Sano T., Fukuda T., Nakajima T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int. J. Cancer. 79:1998;215-220.
27. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
28. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E.et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11891-11896.
29. Kersting M., Friedl C., Kraus A., Behn M., Pankow W., Schuermann M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 18:2000;3221-3229.
30. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G.et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958.
31. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. Springer; 1999.
32. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. Wiley; 2002.
33. Zhang L., Gao W., Gealy R., Weissfeld J., Elder E., Whiteside T.et al. Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers. 8:2003;156-161.
34. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9821-9826.
35. Grunau C., Clark S.J., Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucl. Acids Res. 29:2001;e65.
36. Roncalli M., Bianchi P., Bruni B., Laghi L., Destro A., Di Gioia S.et al. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology. 36:2002;427-432.
37. Ward R., Hawkins N., O'Grady R., Sheehan C., O'Connor T., Impey H.et al. Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am. J. Pathol. 153:1998;373-379.
38. Ng C.S., Zhang J., Wan S., Lee T.W., Arifi A.A., Mok T.et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J. Surg. Oncol. 79:2002;101-106.
39. Graziano S.L., Gamble G.P., Newman N.B., Abbott L.Z., Rooney M., Mookherjee S.et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J. Clin. Oncol. 17:1999;668-675.
40. Ichikawa T., Yano Y., Uchida M., Otani S., Hagiwara K., Yano T. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett. 107:1996;165-170.
41. Yano T., Uchida M., Yuasa M., Murakami A., Hagiwara K., Ichikawa T. The inhibitory effect of vitamin E on K-ras mutation at an early stage of lung carcinogenesis in mice. Eur. J. Pharmacol. 323:1997;99-102.
42. Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A.et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62:2002;2370-2377.